CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both

Stephen J. Nicholls

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)


Inhibitors of cholesteryl ester transfer protein (CETP) were developed due to their ability to raise HDL-C levels. Preclinical studies demonstrated favorable effects on atherosclerotic plaque with CETP inhibitory approaches in animal models. While these agents raise HDL-C and lower LDL-C, most have not proven to reduce cardiovascular event rates in large outcome trials. The state of opinion after all of these clinical trials is reviewed.

Original languageEnglish
Pages (from-to)297-300
Number of pages4
JournalClinical Pharmacology and Therapeutics
Issue number2
Publication statusPublished or Issued - Aug 2018

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this